188 related articles for article (PubMed ID: 16385626)
21. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha.
Martina BE; Koraka P; van den Doel P; Rimmelzwaan GF; Haagmans BL; Osterhaus AD
Virus Res; 2008 Jul; 135(1):64-71. PubMed ID: 18405996
[TBL] [Abstract][Full Text] [Related]
22. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
Lenz P; Lowy DR; Schiller JT
Eur J Immunol; 2005 May; 35(5):1548-56. PubMed ID: 15832296
[TBL] [Abstract][Full Text] [Related]
23. Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes.
Stax MJ; van Montfort T; Sprenger RR; Melchers M; Sanders RW; van Leeuwen E; Repping S; Pollakis G; Speijer D; Paxton WA
Virology; 2009 Sep; 391(2):203-11. PubMed ID: 19682628
[TBL] [Abstract][Full Text] [Related]
24. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.
Balzarini J; Van Herrewege Y; Vermeire K; Vanham G; Schols D
Mol Pharmacol; 2007 Jan; 71(1):3-11. PubMed ID: 17056872
[TBL] [Abstract][Full Text] [Related]
25. Measles virus targets DC-SIGN to enhance dendritic cell infection.
de Witte L; Abt M; Schneider-Schaulies S; van Kooyk Y; Geijtenbeek TB
J Virol; 2006 Apr; 80(7):3477-86. PubMed ID: 16537615
[TBL] [Abstract][Full Text] [Related]
26. DC-SIGN (CD209) recognition of Neisseria gonorrhoeae is circumvented by lipooligosaccharide variation.
Zhang P; Schwartz O; Pantelic M; Li G; Knazze Q; Nobile C; Radovich M; He J; Hong SC; Klena J; Chen T
J Leukoc Biol; 2006 Apr; 79(4):731-8. PubMed ID: 16461738
[TBL] [Abstract][Full Text] [Related]
27. Interaction of acute lymphopblastic leukemia cells with C-type lectins DC-SIGN and L-SIGN.
Gijzen K; Raymakers RA; Broers KM; Figdor CG; Torensma R
Exp Hematol; 2008 Jul; 36(7):860-70. PubMed ID: 18375037
[TBL] [Abstract][Full Text] [Related]
28. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
29. Identification of mycobacterial alpha-glucan as a novel ligand for DC-SIGN: involvement of mycobacterial capsular polysaccharides in host immune modulation.
Geurtsen J; Chedammi S; Mesters J; Cot M; Driessen NN; Sambou T; Kakutani R; Ummels R; Maaskant J; Takata H; Baba O; Terashima T; Bovin N; Vandenbroucke-Grauls CM; Nigou J; Puzo G; Lemassu A; Daffé M; Appelmelk BJ
J Immunol; 2009 Oct; 183(8):5221-31. PubMed ID: 19783687
[TBL] [Abstract][Full Text] [Related]
30. Distribution and lateral mobility of DC-SIGN on immature dendritic cells--implications for pathogen uptake.
Neumann AK; Thompson NL; Jacobson K
J Cell Sci; 2008 Mar; 121(Pt 5):634-43. PubMed ID: 18270264
[TBL] [Abstract][Full Text] [Related]
31. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.
Nabatov AA; van Montfort T; Geijtenbeek TB; Pollakis G; Paxton WA
FEBS J; 2006 Nov; 273(21):4944-58. PubMed ID: 17010165
[TBL] [Abstract][Full Text] [Related]
32. The DC-SIGN of zebrafish: insights into the existence of a CD209 homologue in a lower vertebrate and its involvement in adaptive immunity.
Lin AF; Xiang LX; Wang QL; Dong WR; Gong YF; Shao JZ
J Immunol; 2009 Dec; 183(11):7398-410. PubMed ID: 19890038
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell-mediated trans-enhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN.
Boggiano C; Manel N; Littman DR
J Virol; 2007 Mar; 81(5):2519-23. PubMed ID: 17182696
[TBL] [Abstract][Full Text] [Related]
34. Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.
Lekkerkerker AN; Ludwig IS; van Vliet SJ; van Kooyk Y; Geijtenbeek TB
Virology; 2004 Nov; 329(2):465-76. PubMed ID: 15518824
[TBL] [Abstract][Full Text] [Related]
35. The physiological role of DC-SIGN: a tale of mice and men.
Garcia-Vallejo JJ; van Kooyk Y
Trends Immunol; 2013 Oct; 34(10):482-6. PubMed ID: 23608151
[TBL] [Abstract][Full Text] [Related]
36. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
37. Induction of Th1/Th17 immune response by Mycobacterium tuberculosis: role of dectin-1, Mannose Receptor, and DC-SIGN.
Zenaro E; Donini M; Dusi S
J Leukoc Biol; 2009 Dec; 86(6):1393-401. PubMed ID: 19773555
[TBL] [Abstract][Full Text] [Related]
38. The C-type lectin DC-SIGN internalizes soluble antigens and HIV-1 virions via a clathrin-dependent mechanism.
Cambi A; Beeren I; Joosten B; Fransen JA; Figdor CG
Eur J Immunol; 2009 Jul; 39(7):1923-8. PubMed ID: 19585517
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms that set the stage for DC-T cell engagement.
van Gisbergen KP; Paessens LC; Geijtenbeek TB; van Kooyk Y
Immunol Lett; 2005 Mar; 97(2):199-208. PubMed ID: 15752559
[TBL] [Abstract][Full Text] [Related]
40. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
